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Human papilloma viruses (HPVs) are accepted as being carcinogenic in human cervical and anogenital cancers. The suspicion that
HPVs may also have a role in human breast cancer is based on the identification of HPVs in human breast tumours and the
immortalisation of normal human breast cells by HPV types 16 and 18. For this investigation, DNA that had been previously extracted
and fresh frozen at  701C from 50 unselected invasive ductal breast cancer specimens were screened by polymerase chain reaction
(PCR) for HPV type 16, 18 and 33 gene sequences. We show that HPV 18 gene sequences are present in DNA extracted from
breast tumours in Australian women. Overall, 24 (48%) of the 50 samples were HPV positive. Overall no correlations with tumour
grade, patient survival, steroid receptor status, ERB-2, p53 expression and mutation were observed. Human papilloma viruses may
have a role in human breast cancer. We speculate that HPVs may be transmitted by hand from the female perineum to the breast.
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It is accepted that human papillomavirus (HPV) types 16 and 18
are carcinogenic, and that probably HPV types 31 and 33 are also
carcinogenic in human cervical and anogenital cancers (IARC,
1995). The suspicion that HPVs may also have a role in human
breast cancer is based on the identification of HPVs in human
breast tumours and the immortalisation of normal human breast
cells by HPV 16 and 18 (Band et al, 1990; De Villiers et al, 2005).
Human papilloma virus 16 has been identified in breast tumours
in Italian women and breast tumours in Norwegian women who
had previous cervical neoplasia (Hennig et al, 1999). Human
papilloma virus 33 has been identified in breast cancer in Chinese
and Japanese women (Yu et al, 1999). Human papilloma virus 11,
16 and 18 have been identified in breast cancer in US and
separately in Brazilian women (Liu et al, 2001; Damin et al, 2004).
No HPVs have been identified in normal breast tissues from
normal women who have had cosmetic surgery. No significant
correlations have been observed between HPVs identified in
human breast cancer and hormone receptor status of the tumour.
Recently, de Villiers et al (2005) have identified a wide range of
HPV types in cancer of the breast and nipples (De Villiers et al,
2005). In this latter investigation, the cancer of the nipple
specimens had histological features consistent with human HPV
infections. Other investigators have sought, but failed, to identify
HPVs in human breast tumours. These various studies have been
briefly reviewed by De Villiers et al (2005).
The aims of our investigation are to determine: (1) if HPV types
16, 18 and 33 gene sequences (the most common HPV carcinogens
in cervical cancer) are present in breast cancers that have occurred
in predominantly Caucasian Australian women, and (2) if there are
any correlations between the presence of HPV sequences and
grade of tumour, patient mortality, hormone receptor status,
abnormal p53 protein expression, the presence of p53 mutations
and ERB-2 expression.
MATERIALS AND METHODS
For this investigation, DNA that had been previously extracted and
fresh frozen at  70
OC from 50 unselected invasive ductal breast
cancer specimens were screened by polymerase chain reaction
(PCR) for HPV type 16, 18 and 33 gene sequences. The DNA
samples were amplified twice per sample using GenomiPhit DNA
Amplification Kit (Amersham Biosciences). The DNA quality was
confirmed by PCR, amplifying 268bp of the b-globin gene. These
samples were then screened for the presence of HPV by PCR using
primers that could detect 140bp in the E6 region of HPV 16, 18
and 33 (Yu et al, 1999). DNA extracted from cervical cancer cell
lines HeLa and SiHa cells were used as positive controls for HPV
18 and 16, respectively. Plasmid plink 322 HPV 33 was used as a
positive control for HPV 33. DNA from leukaemia Raji cells was
used a negative control. The PCR products were separated on 7.6%
PAGE and visualised by SYBR Green I (Molecular Probes). The
screening was repeated five times using different batches of DNA
samples amplified by the GenomiPhit DNA Amplification Kit
(Amersham Biosciences). Human papilloma virus-positive sam-
ples were sequenced (there was sufficient material to sequence 18
of 24 HPV-positive samples).
Grade of tumour and survival of patients were known for each
sample. Screening for exons 5–8 inclusive of the p53 gene were
carried out using PCR–SSCP techniques as described and reported Received 4 April 2005; revised 25 July 2005; accepted 11 August 2005
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searlier by our group for this tumour series (Soong et al, 1997).
Overexpression of p53 protein in primary breast tumours was
investigated using immunohistochemistry with the DO7 monoclonal
antibody as reported previously (Soong et al, 1997). Steroid receptor
concentrations and ERB2 gene amplification were determined as
previously described and reported (Soong et al,1 9 9 7 ) .
RESULTS
Overall, 24 (48%) of the 50 samples were HPV positive. Sequencing
of 18 unselected samples showed them to be variants of HPV 18
(there was insufficient material to sequence six of the 24 positive
samples). In each separate PCR the percentage of breast cancer
DNA samples that was HPV positive ranged from 2 to 32%. An
added amplification of DNA before PCR and use of SYBR Green I
for detection improved viral detection. As shown in Figure 1, there
were five variants of HPV 18 sequences identified among the 18
sequenced samples. Such variations indicate that the presence of
HPV 18 sequences is not due to contamination.
As shown in Table 1, there were no significant correlations
between grade of tumour, mortality of patients, ER alpha, PR,
ERB-2, p53 expression and the presence of p53 mutations.
DISCUSSION
These results confirm the presence of HPV 18 gene sequences in
human breast tumours. The identification of such sequences
HPV18 (M20324)AAGGGAGTAACCGAAAACGGTCGGGACCGAAAACGGTGTATATAAAAGATGTGAGAAACA  
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Figure 1 HPV DNA sequences. The DNA sequences of 18 HPV-positive samples were compared with the HPV 18E6 sequence (accession number:
M20324) in the National Centre for Biotechnology Information database by the BLASTn program. Five variants of HPV 18 were identified.
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DNA before PCR and use of SYBR Green I to optimise the
detection. These technical difficulties may account for the negative
results obtained in several other studies (reviewed in three).
We did not identify HPV types 16 and 33 in these breast
tumours. A plausible explanation is that HPV 18 may be present in
breast tumours in predominantly Caucasian populations and HPV
33 in breast tumours that occur in predominantly Chinese and
Japanese populations (Hennig et al, 1999; Yu et al, 1999; De Villiers
et al, 2005).
Five variants of HPV 18 were identified. Variations in the gene
sequences indicate that these were not contaminants. Sequence
variations were observed in the Sp1-binding site, E2 protein-
binding site number 2, between E2 protein-binding site number 1
and 2, a region 12bp upstream of the first starting codon, and
within the translated E6 sequence. As far as we know, these
variations are novel and no one has yet studied the effect of these
variations on the expression of HPV genes. However, it is
anticipated that these variations would not have an impact on
the HPV gene expression. This is because those variations do not
alter the SP1 and E2 protein-binding motifs, and the base pair
change does not alter the E6 amino-acid sequence.
The role of HPV in breast cancer development is not elucidated.
As in other studies, the presence of HPV sequences in breast tumour
samples is not associated with tumour grade, patient mortality,
expression of ER, PR, ERB-2, p53 expression and mutation. Hence,
it is not clear if HPV promotes cancer development or the presence
of HPV sequences represents a parasitic infection independent of
cancer. However, given that HPVs are proven human oncoviruses in
cervical cancer, it is unlikely that they act as parasitic infections in
human breast tumours.
Human papilloma viruses are mainly transmitted by cell surface
contact. Therefore, how are HPVs transmitted to the breast? A
suggestive clue comes from the observation by de Villiers et al
(2005) that HPVs are present in cancers occurring in human nipple
milk ducts and that these cancers have the typical histological
features of HPV-induced human cancers. In addition, in two
independent studies, HPV 16 has been found to be present in breast
tumours that occur in European women with HPV 16-associated
cervical cancer (Hennig et al, 1999; Widschwendter et al,2 0 0 4 ) .
Virions (virus particles) are shed from desquamating keratinocytes
(the target cells for HPV infections) and high-risk HPVs can be
transmitted by close human nonsexual contact (Bryan and Brown,
2001; Rintala et al, 2005). Accordingly, we speculate that HPVs may
be transmitted by hand from the female perineum to the breast
which could occur, for example, during showering or bathing.
In conclusion, our studies demonstrate the presence of HPV 18
variants in Australian breast cancer specimens. Further studies
are required to elucidate the role and pathogenesis of HPV in
breast cancer.
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Table 1 Presence of HPV gene sequences in DNA extracted from 50
human breast tumours
Correlations of the
presence of HPV
a with
Spearman’s
correlation coefficient
b
Two-tailed
significance
c
Tumour grade 0.127 0.378NS
Patient’s mortality
d  0.107 0.461NS
ER-positive tumour
e 0.132 0.364NS
PR-positive tumour
f 0.104 0.479NS
ERB
g receptor 0.089 0.591NS
p53
h expression 0.090 0.533NS
p53
i mutation  0.103 0.478NS
aSamples which have HPV sequences identified at least once by PCR are included in
the statistical analysis and considered as HPV positive.
bSpearman’s rank order
correlation for nonparametric data. The correlation coefficient ranges from  1t o1
for perfect correlations.
cThe significance is two-tailed. NS¼not significant at 95%
level.
dMortality¼death due to recurrence of breast cancer (eight patients).
eER¼oestrogen receptor positively expressed in at least 5% of cancer cells.
fPR¼progesterone receptor expressed in at least 5% of cancer cells.
gERB¼ERB
receptor expressed in the cytoplasm of cancer cells.
hp53 expression¼p53 protein
expressed in at least 5% of cancer cells.
ip53 mut¼p53 mutations identified in cancer
cells. Correlations with grade, survival, ER, PR, ERB-2, P53 expression and p53
mutations.
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